GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sarepta Therapeutics Inc (STU:AB3A) » Definitions » Cyclically Adjusted FCF per Share

Sarepta Therapeutics (STU:AB3A) Cyclically Adjusted FCF per Share : €-5.37 (As of Mar. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Sarepta Therapeutics Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Sarepta Therapeutics's adjusted free cash flow per share for the three months ended in Mar. 2024 was €-2.641. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-5.37 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -14.20% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -11.50% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was -11.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Sarepta Therapeutics was 13.00% per year. The lowest was -16.60% per year. And the median was -4.00% per year.

As of today (2024-06-07), Sarepta Therapeutics's current stock price is €107.55. Sarepta Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was €-5.37. Sarepta Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Sarepta Therapeutics Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Sarepta Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sarepta Therapeutics Cyclically Adjusted FCF per Share Chart

Sarepta Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.46 -3.05 -3.97 -4.57 -5.05

Sarepta Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.84 -4.86 -5.34 -5.05 -5.37

Competitive Comparison of Sarepta Therapeutics's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Sarepta Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sarepta Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sarepta Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Sarepta Therapeutics's Cyclically Adjusted Price-to-FCF falls into.



Sarepta Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Sarepta Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-2.641/131.7762*131.7762
=-2.641

Current CPI (Mar. 2024) = 131.7762.

Sarepta Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.819 100.560 -1.073
201409 -0.911 100.428 -1.195
201412 -0.567 99.070 -0.754
201503 -0.990 99.621 -1.310
201506 -0.634 100.684 -0.830
201509 -1.025 100.392 -1.345
201512 -0.671 99.792 -0.886
201603 -1.224 100.470 -1.605
201606 -0.850 101.688 -1.102
201609 -1.141 101.861 -1.476
201612 -1.467 101.863 -1.898
201703 -1.062 102.862 -1.361
201706 -1.431 103.349 -1.825
201709 -0.895 104.136 -1.133
201712 -0.471 104.011 -0.597
201803 -0.609 105.290 -0.762
201806 -1.658 106.317 -2.055
201809 -1.741 106.507 -2.154
201812 -1.793 105.998 -2.229
201903 -2.005 107.251 -2.463
201906 -1.145 108.070 -1.396
201909 -0.941 108.329 -1.145
201912 -2.185 108.420 -2.656
202003 7.325 108.902 8.864
202006 -1.444 108.767 -1.749
202009 -2.850 109.815 -3.420
202012 -2.116 109.897 -2.537
202103 -2.131 111.754 -2.513
202106 -1.197 114.631 -1.376
202109 -1.421 115.734 -1.618
202112 -0.348 117.630 -0.390
202203 -1.111 121.301 -1.207
202206 -0.820 125.017 -0.864
202209 -0.858 125.227 -0.903
202212 -1.081 125.222 -1.138
202303 -2.319 127.348 -2.400
202306 -1.457 128.729 -1.491
202309 -1.640 129.860 -1.664
202312 -0.651 129.419 -0.663
202403 -2.641 131.776 -2.641

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Sarepta Therapeutics  (STU:AB3A) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Sarepta Therapeutics Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Sarepta Therapeutics's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Sarepta Therapeutics (STU:AB3A) Business Description

Industry
Traded in Other Exchanges
Address
215 First Street, Suite 415, Cambridge, MA, USA, 02142
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development.

Sarepta Therapeutics (STU:AB3A) Headlines

No Headlines